Frailty in Childhood Cancer Survivors as Premature Aging Marker
Current understanding
Young adult survivors of childhood cancer show a physical frailty phenotype (Fried-style: grip weakness, slow gait, exhaustion, low activity, weight loss) at prevalence rates typically seen in geriatric populations, and this phenotype has been associated observationally with chronic disease, hospitalization, and excess mortality in this cohort [human-observational]. A planned five-year longitudinal characterization aims to test whether serial frailty scoring identifies survivors at greatest risk and could serve as a premature-aging risk marker for preventive intervention [human-observational]. As with all aging-phenotype scores, frailty is a functional composite, not a direct measurement of biological aging, and its predictive validity in this young population is still being characterized.
Evidence log
- 2026-09-30 — An Open-Label Intervention Trial to Reduce Senescence and Improve Frailty in Adult Survivors of Childhood Cancer: cross-connection with senescent-burden-biomarkers: Pilot pairs blood p16INK4a senescence burden with gait-speed/frailty measures in childhood-cancer survivors, explicitly testing whether a senolytic-responsive senescence marker tracks the premature-aging frailty phenotype in this population. (novelty: 3)
- 2026-06-17 — A Longitudinal Assessment of Frailty in Young Adult Survivors of Childhood Cancer: cross-connection with frailty-assessment-tools: Frailty scales developed for perioperative geriatric risk are being repurposed to detect premature aging in young cancer survivors. (novelty: 3)